Tema Oncology ETF (NASDAQ:CANC) Short Interest Down 69.4% in March

Tema Oncology ETF (NASDAQ:CANC) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 2,200 shares, a decline of 69.4% from the February 28th total of 7,200 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 19,200 shares, the days-to-cover ratio is presently 0.1 days.

Tema Oncology ETF Trading Down 0.4 %

Shares of CANC traded down $0.10 during mid-day trading on Friday, reaching $24.53. 6,347 shares of the stock traded hands, compared to its average volume of 11,430. The firm has a fifty day moving average price of $25.27 and a 200 day moving average price of $26.43. Tema Oncology ETF has a 1 year low of $23.97 and a 1 year high of $30.11. The company has a market cap of $62.55 million, a price-to-earnings ratio of 23.50 and a beta of 1.11.

Hedge Funds Weigh In On Tema Oncology ETF

An institutional investor recently raised its position in Tema Oncology ETF stock. Thrivent Financial for Lutherans raised its stake in shares of Tema Oncology ETF (NASDAQ:CANC) by 29.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 517,837 shares of the company’s stock after purchasing an additional 118,328 shares during the quarter. Thrivent Financial for Lutherans owned approximately 20.31% of Tema Oncology ETF worth $13,156,000 at the end of the most recent reporting period.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.